883992-68-5

Basic information

• Product Name: N¹-methyl-5-(trifluoromethyl)benzene-1,2-diamine
• Synonyms: N¹-methyl-5-(trifluoromethyl)benzene-1,2-diamine
• CAS NO: 883992-68-5
• Molecular Weight: 190.168
• Mol File: 883992-68-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N¹-methyl-5-(trifluoromethyl)benzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N¹-methyl-5-(trifluoromethyl)benzene-1,2-diamine(883992-68-5)
• EPA Substance Registry System: N¹-methyl-5-(trifluoromethyl)benzene-1,2-diamine(883992-68-5)

Safety Data

• Hazardous Substances Data: 883992-68-5(Hazardous Substances Data)

Upstream product

• 402-11-9 3-chloro-4-nitrobenzotrifluoride 
• 98-16-8 3-trifluoromethylaniline 
• 395-99-3 N-[2-nitro-5-(trifluoromethyl)phenyl]acetamide 
• 402-14-2 2-nitro-5-(trifluoromethyl)aniline 
• 1997-46-2 2,2,2-trifluoro-N-[2-nitro-5-(trifluoromethyl)phenyl]acetamide 
• 883992-66-3 N-methyl-N-[2-nitro-5-(trifluoromethyl)phenyl]acetamide 
• 883992-67-4 N-methyl-2-nitro-5-(trifluoromethyl)aniline 

Downstream Products

• 397869-98-6 1-methyl-6-(trifluoromethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

C2-Selective Branched Alkylation of Benzimidazoles by Rhodium(I)-Catalyzed C-H Activation

Herein, we report a Rh(I)/bisphosphine/K3PO4 catalytic system allowing for the first time the selective branched C-H alkylation of benzimidazoles with Michael acceptors. Branched alkylation with N,N-dimethyl acrylamide was successfully applied to the alkylation of a broad range of benzimidazoles incorporating a variety of N-substituents and with both electron-rich and -poor functionality displayed at different sites of the arene. Moreover, the introduction of a quaternary carbon was achieved by alkylation with ethyl methacrylate. The method was also shown to be applicable to the C2-selective branched alkylation of azabenzimidazoles.

Synthesis and antiprotozoal activity of some 2-(trifluoromethyl)-1H- benzimidazole bioisosteres

A series of 2-(trifluoromethyl)-1H-benzimidazole derivatives with various 5- and 6-position bioisosteric substituents (-Cl, -F, -CF3, -CN), namely 1-7, were prepared using a short synthetic route. Each analogue was tested in vitro against the protozoa Giardia intestinalis and Trichomonas vaginalis in comparison with albendazole and metronidazole. Several analogues had IC50 values 1 μM against both species, which make them significantly more potent than either standard. Compound 4 [2,5(6)- bis(trifluoromethyl)-1H-benzimidazole], was 14 times more active than albendazole against T.:vaginalis. This compound (4) also showed moderate antimalarial activity against W2 and D6 strains of Plasmodium falciparum (5.98 and 6.12 μM, respectively). Studying further structure activity relationships through the use of bioisosteric substitution in these benzimidazolic derivatives should provide new leads against protozoal and possibly malarial diseases.